List view / Grid view

News

NICE recommends melanoma drug pembrolizumab

7 September 2015 | By Victoria White

NICE has recommended that pembrolizumab is made available on the NHS as a treatment for some patients with advanced melanoma which is either unresectable or metastatic...

Faron announces intention to float on AIM

7 September 2015 | By Victoria White

Faron's admission to AIM will support development of its lead candidate, Traumakine, into a Phase III Study and the development of its preclinical cancer immunotherapy candidate, Clevegen...

EC approves multiple myeloma treatment Farydak

4 September 2015 | By Victoria White

The EC has approved Farydak in combination with bortezomib and dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma...

Amgen submits MAA for etelcalcetide to the EMA

3 September 2015 | By Victoria White

If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously for the treatment of SHPT in patients with chronic kidney disease...

UCB to sell Kremers Urban to Lannett

3 September 2015 | By Victoria White

Lannett Company has entered into a definitive agreement to acquire UCB’s US generics subsidiary, Kremers Urban Pharmaceuticals, for $1.23 billion...

FDA grants Fast Track designation to iclaprim

3 September 2015 | By Victoria White

The FDA has granted Fast Track designation to iclaprim to treat acute bacterial skin and skin structure infections and hospital acquired bacterial pneumonia...